An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings

Primary Care Diabetes

Volumn 6, Issue 4, 2012, Pages 303-312

  De Salas Cansado, Marina ^a   Pérez, Concepción ^b   Saldaña, María T ^c   Navarro, Ana ^d   González Gómez, Francisco J ^e   Ruiz, Lucía ^a   Rejas, Javier ^f  

^a TFS People   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Primary Care Health Centre Raices   (Spain)

^d Puerta Del Ángel Primary Care Center   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f PFIZER INC   (United States)

Author keywords

Cost effectiveness; Painful diabetic peripheral neuropathy; Pregabalin; QALY; Refractory; Usual care

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DIPYRONE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PREGABALIN; TRAMADOL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BOOTSTRAPPING; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NEUROPATHIC PAIN; OUTPATIENT CARE; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REFRACTORY PAINFUL DIABETIC PERIPHERAL NEUROPATHY; REGISTER; SENSITIVITY ANALYSIS; SPAIN; TREATMENT OUTCOME;

AGED; ANALGESICS; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COMMUNITY HEALTH SERVICES; COST-BENEFIT ANALYSIS; DIABETIC NEUROPATHIES; DRUG COSTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PAIN MEASUREMENT; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869092692     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2012.03.001     Document Type: Article

References (37)

1. R.D. Treede Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology 70 2008 1630 1635
2. R. Gálvez, J. Rejas, M. Pérez, and M. Gómez Prevalence of neuropathic pain in Spain: clinical, working and health care implications Med. Clin. (Barcelona) 125 2005 221 229 (Pubitemid 41153550)
3. W. Pluijims, F. Huygen, and J. Cheng Evidence-based interventional pain medicine according to clinical diagnoses. Painful diabetic polyneuropathy Pain Pract. 11 2011 191 198
4. K.E. Schmader Epidemiology and impact on quality of life of post-herpetic neuralgia and painful diabetic neuropathy Clin. J. Pain 18 2002 350 354 (Pubitemid 35291575)
5. G.C. Hall, D. Carroll, and D. Parry Epidemiology and treatment of neuropathic pain: the UK primary perspective Pain 122 1-2 2006 156 162
6. S. Quilici, J. Chancellor, and Löthgren Meta-analysis of duloxetine vs. pregabalin and gabapentine in the treatment of diabetic peripheral neuropathic pain BMC Neurol. 9 2009 6 10.1186/1471-2377-9-6
7. L.A. McWilliams, R.D. Goodwin, and B.J. Cox Depression and anxiety associated with three pain conditions: results from a nationally representative sample Pain 111 2004 77 83 (Pubitemid 39141009)
8. M. Gore, N.A. Brandenburg, E. Dukes, D.L. Hoffman, K.S. Tai, and B. Stacey Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep J. Pain Symptom Manage. 30 2005 374 385 (Pubitemid 41527124)
9. C.E. Argoff The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach Clin. J. Pain 23 2007 15 22
10. R.M. Gallagher, and S. Verma Managing pain and comorbid depression: a public health challenge Semin. Clin. Neuropsychiatry 4 1999 203 220
11. M.T. Smith, and J.A. Haythornthwaite How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature Sleep Med. Rev. 8 2004 119 132 (Pubitemid 38445487)
12. C.J. Currie, C.D. Poole, A. Woehl, C.L. Morgan, S. Cawley, M.D. Rousculp, M.T. Covington, and J.R. Peters The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy Diabet. Med. 24 2007 187 194 (Pubitemid 46174943)
13. M.J. Rodríguez, and A.J. García A registry of the aetiology and costs of neuropathic pain in pain clinics: results of the registry of etiologies and costs (REC) in neuropathic pain disorders study Clin. Drug Invest. 27 2007 771 782 (Pubitemid 47529293)
14. A. Berger, E.M. Dukes, and G. Oster Clinical characteristics and economic costs of patients with painful neuropathic disorders J. Pain 5 2004 143 149 (Pubitemid 38879392)
15. A. Gordois, P. Schuffham, and A. Shearer The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care 26 2003 1790 1795 (Pubitemid 36929121)
16. G. Cruccu, C. Sommer, P. Anand, N. Attal, R. Baron, L. Garcia-Larrea, M. Haanpaa, T.S. Jense, J. Serra, and R.D. Treede EFNS panel on neuropathic pain. A. EFNS guidelines on neuropathic pain assessment: revised 2009 Eur. J. Neurol. 17 2010 1010 1018
17. N. Attal, G. Cruccu, R. Baron, M. Haanpää, P. Hansson, T.S. Jensen, T. Nurmikko European Federation of Neurological Societies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision Eur. J. Neurol. 17 9 2010 1113 1123
18. NICE Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings NICE Guidel. 96 2010 1 155
19. D.M. Tassone, E. Boyce, J. Guyer, and D. Nuzum Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders Clin. Ther. 29 2007 26 48 (Pubitemid 46415802)
20. I. Gilron Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions Curr. Opin. Anaesthesiol. 20 2007 456 472 (Pubitemid 47415136)
21. R. Freynhagen, K. Strojek, T. Griesing, E. Whalen, and M. Balkenohl Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens Pain 115 2005 254 263 (Pubitemid 40725282)
22. R.H. Dworkin, A.E. Corbin, J.P. Young Jr., U. Sharma, L. LaMoreaux, H. Bockbrader, E.A. Garofalo, and R.M. Poole Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial Neurology 60 2003 1274 1283 (Pubitemid 36460982)
23. R. Sabatowski, R. Galvez, D.A. Cherry, F. Jacquot, E. Vincent, P. Maisonobe, M. Versavel 1008-045 Study Group Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial Pain 109 2004 26 35 (Pubitemid 38479767)
24. M.J. Rodríguez, S. Díaz, M. Vera-Llonch, E. Dukes, and J. Rejas Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Curr. Med. Res. Opin. 23 2007 2585 2596 (Pubitemid 350033461)
25. A. Johnston, and K. Hamandi Cost-effectiveness of pregabalin: a UK perspective Expert Rev. Pharmacoecon. Outcomes Res. 7 2007 327 333 (Pubitemid 47365010)
26. J.E. Tarride, A. Gordon, M. Vera-Llonch, E. Dukes, and C. Rousseau Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective Clin. Ther. 28 2006 1922 1934 (Pubitemid 46043510)
27. P.D. Stolley, and J. Laporte The public health, the university, and pharmacoepidemiology B>L. Strom, Pharmacoepidemiology third ed. 2000 John Wiley & Sons
28. R.M. Gallagher Naturalistic study designs in samples with refractory pain: advantages and limitations Pain Med. 5 2004 143 145 (Pubitemid 39029244)
29. A. Navarro, M.T. Saldaña, C. Pérez, S. Torrades, and J. Rejas Patient-reported-outcomes in subjects with neuropathic pain receiving pregabalin: evidence from the medical practice in primary care settings Pain Med. 11 2010 719 731
30. J.A. Sacristán, J. Oliva, J. Del Llano, L. Prieto, and J.L. Pinto ¿Qué es una tecnología sanitaria eficiente en España? Gac. Sanit. 4 2002 334 343
31. W.F. Stewart, R.B. Lipton, and D. Simon Work-related disability: results from the American migrNSAIDs study Cephalalgia 16 1996 231 238 (Pubitemid 26189248)
32. Catálogo de Especialidades Farmacéuticas 2006. Consejo General de Colegios Oficiales de Farmacéuticos, Madrid, 2006.
33. Oblikue S.C.d.E.e.E.d.l.S.y.P. Social, eSALUD, Base de datos de costes sanitarios 2006 SOIKOS Barcelona
34. Instituto Nacional de Estadística, Encuesta Trimestral de Coste Laboral, Available in: http://www.ine.es/daco/daco42/etcl/etcl0405.pdf (updated: 15/03/2006; accessed 02.10.2006).
35. R. Brooks EuroQoL: the current state of play Health Policy 37 1996 53 72 (Pubitemid 26191458)
36. A.B. O'Connor, K. Noyes, and R.G. Holloway A cost-utility comparison of four first-line medications in painful diabetic neuropathy Pharmacoeconomics 26 2008 1045 1064
37. A.B. O'Connor, K. Noyes, and R.G. Holloway A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia J. Am. Geriatr. Soc. 55 2007 1176 1184 (Pubitemid 47106676)